What is the regulatory status of Semaglutide (GLP-1)?

Semaglutide (GLP-1) regulatory status: Approved (Ozempic 2017, Wegovy 2021) in the United States; WADA status not on prohibited list; research level extensive phase iii and post-marketing. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For scheduling and cycle use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

Is Semaglutide (GLP-1) safe during pregnancy or breastfeeding?

Semaglutide (GLP-1), like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

How long until I see results from Semaglutide (GLP-1)?

Acute effects from Semaglutide (GLP-1) appear within the first week for downstream physiological adaptation. scheduling and cycle endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What is the evidence base for Semaglutide (GLP-1)?

Semaglutide (GLP-1)'s evidence base sits at extensive phase iii and post-marketing. The references on this page summarise 3 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The protocol / scheduling / cycling interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

What does Semaglutide (GLP-1) stack well with?

For protocol / scheduling / cycling protocols, Semaglutide (GLP-1) pairs with compounds on complementary pathways: BPC-157, TB-500, Ipamorelin. These pairings are selected because they engage independent receptor systems from Semaglutide (GLP-1)'s primary mechanism (Selective GLP-1 receptor agonist), producing additive or synergistic effects rather than receptor competition.

Home/ Compounds/ Semaglutide (GLP-1)

Semaglutide (GLP-1)

Protocol

Protocol design for Semaglutide (GLP-1) starts with pharmacokinetics and ends with calendar planning. The compound's ~7 days half-life via subq/oral (rybelsus, 7-14 mg daily) administration places it in the weekly-dosing bucket; cycle length is 8-12 weeks with a 4-week off-period; stack integration follows route compatibility and receptor non-overlap principles.

Protocol / Scheduling / Cycling Applications

Weekly TimingProtocol CalendarMaintenance PhasePeriodised CyclesMulti-Peptide Timing

Key Takeaways

Scheduling lens: Semaglutide (GLP-1)'s ~7 days half-life via subq/oral (rybelsus, 7-14 mg daily) places it in the weekly-dosing bucket.
Mechanism: Selective GLP-1 receptor agonist.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Selective GLP-1 receptor agonist. Augments glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally in the arcuate nucleus to suppress appetite. Fatty acid sidechain and substitutions extend half-life to ~7 days. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for Semaglutide (GLP-1).

Cycle length and off-cycle planning

Standard Semaglutide (GLP-1) cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Stack scheduling with other compounds

When Semaglutide (GLP-1) is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Multiple subcutaneous compounds can be combined in a single injection where compatible, or staggered through the day where pharmacokinetics differ meaningfully. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Semaglutide (GLP-1) protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Semaglutide (GLP-1) schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Protocol / Scheduling / Cycling Applications

Stack Scheduling

The most-asked scheduling question for Semaglutide (GLP-1) in stack scheduling is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Loading Phase

Schedule design for Semaglutide (GLP-1) in loading phase starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Weekly Timing

For weekly timing scheduling, Semaglutide (GLP-1) is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Protocol Calendar

The most-asked scheduling question for Semaglutide (GLP-1) in protocol calendar is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	0.25-2.4 mg weekly (titrated)	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.25-2.4 mg weekly (titrated)	4–6 weeks initial cycle
Protocol focus	SubQ	0.25-2.4 mg weekly (titrated)	1x weekly SubQ
Maintenance phase	SubQ	1.25-2.4 mg weekly (titrated)	Ongoing with periodic pauses

Dose timing for Semaglutide (GLP-1) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Semaglutide (GLP-1) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

Semaglutide (GLP-1) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Semaglutide (GLP-1)'s mechanism in protocol / scheduling / cycling protocols.
Semaglutide (GLP-1) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Semaglutide (GLP-1)'s mechanism in protocol / scheduling / cycling protocols.
Semaglutide (GLP-1) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Semaglutide (GLP-1)'s mechanism in protocol / scheduling / cycling protocols.
Semaglutide (GLP-1) + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Semaglutide (GLP-1)'s mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Approved (Ozempic 2017, Wegovy 2021) Research: Extensive Phase III and post-marketing

GI events (nausea, vomiting, constipation) most common. Pancreatitis caution. Avoid in personal/family history of medullary thyroid carcinoma or MEN-2. Pregnancy: contraindicated.

Lens-specific safety considerations for protocol / scheduling / cycling use of Semaglutide (GLP-1): GI events (nausea, vomiting, constipation) most common. Pancreatitis caution. Avoid in personal/family history of medullary thyroid carcinoma or MEN-2. Pregnancy: contraindicated. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

STEP 1 — Once-weekly semaglutide in adults with overweight or obesity

PMID 33567185

Supporting

STEP 2 — Semaglutide in type 2 diabetes and obesity

PMID 33567186

Semaglutide (GLP-1) vs Related Peptides

Compound	Profile	Onset	Best For
Semaglutide (GLP-1)	GLP-1 receptor agonist	~7 days	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Can I shift my schedule with travel?

Up to ±8 hours of timing shift has no clinical effect for most peptide schedules. Time-zone changes longer than 8 hours warrant a minor schedule adjustment over 1–2 days to re-anchor the cycle. Cold-chain requirements during travel are the more important operational concern.

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

Daily timing for Semaglutide (GLP-1)?

Pragmatic timing depends on pharmacokinetics: single weekly dose for long half-life. Consistent timing matters more than the absolute clock time of any single dose.

Stack timing relative to training and meals?

Fasted dosing for GH-axis and AMPK-engaging compounds; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it. Training-day-only versus daily dosing depends on the compound and the volume of training; verify against the specific protocol.

How does Semaglutide (GLP-1)'s half-life affect dosing?

Semaglutide (GLP-1) has a plasma half-life of ~7 days, which is long enough that single-weekly dosing is operationally viable. The receptor occupancy curve under 1x weekly subq dosing at 0.25-2.4 mg weekly (titrated) per dose explains the typical onset timeline for scheduling and cycle endpoints.

What are the safety considerations for Semaglutide (GLP-1)?

GI events (nausea, vomiting, constipation) most common. Pancreatitis caution. Avoid in personal/family history of medullary thyroid carcinoma or MEN-2. Pregnancy: contraindicated. For scheduling and cycle use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Semaglutide (GLP-1)'s ~7 days pharmacokinetic profile and subq/oral (rybelsus, 7-14 mg daily) administration route influence the side-effect profile in predictable ways.

Clinical Protocol

Start a Semaglutide (GLP-1) Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified Semaglutide (GLP-1) and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: ~4114 Da
Sequence length: 31 aa
Half-life: ~7 days
WADA: Not on prohibited list
FDA: Approved (Ozempic 2017, Wegovy 2021)
Research: Extensive Phase III and post-marketing

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Semaglutide (GLP-1) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for Semaglutide (GLP-1)

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised